Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVER: Nitazoxanide or Sofosbuvir/Daclatasvir for COVID-19 Prevention
NCT04561063Phase 2Completed
- Sponsor
- University of the Witwatersrand
- Start
- Dec 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nitazoxanide, sofosbuvir and daclatasvir in coronavirus disease 2019 (COVID-19), sponsored by University of the Witwatersrand. Primary endpoint: Number of SARS-CoV-2 infections at 6 months. Started Dec 2020; status: completed.
02
Drugs
nitazoxanidesofosbuvirdaclatasvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04561063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04561063.